Fed Regist. 1999 May 10;64(89):25049-50.
The Food and Drug Administration (FDA) is announcing the availability of a document entitled "Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use.'" This guidance document is intended to assist applicants in the preparation of the content and format of the chemistry, manufacturing, and controls (CMC) section and the establishment description section of a biologics license application (BLA), revised Form FDA 356h, for human blood and blood components intended for transfusion or for further manufacture. In addition, this guidance document provides assistance for the completion of the BLA. This action is part of FDA's continuing effort to achieve the objectives of the President's "Reinventing Government" initiatives and the Food and Drug Administration Modernization Act of 1997 (Modernization Act), to reduce unnecessary burdens for industry without diminishing public health protection.
美国食品药品监督管理局(FDA)宣布可获取一份题为“行业指南:用于提交供输血或进一步制造的人血及血液成分的化学、制造与控制以及机构描述信息,以及填写FDA 356h表格‘人用新药、生物制品或抗生素药物上市申请’”的文件。本指南文件旨在协助申请人准备用于输血或进一步制造的人血及血液成分的生物制品许可申请(BLA)(修订后的FDA 356h表格)的化学、制造与控制(CMC)部分以及机构描述部分的内容和格式。此外,本指南文件还为完成BLA申请提供帮助。此行动是FDA持续努力的一部分,以实现总统“重塑政府”倡议和1997年《食品药品管理局现代化法案》(《现代化法案》)的目标,在不削弱公共卫生保护的情况下减轻行业不必要的负担。